Saeki H - Search Results

1

Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer.

Nambara S, Masuda T, Nishio M, Kuramitsu S, Tobo T, Ogawa Y, Hu Q, Iguchi T, Kuroda Y, Ito S, Eguchi H, Sugimachi K, Saeki H, Oki E, Maehara Y, Suzuki A, Mimori K. Nambara S, et al. Among authors: saeki h. Oncotarget. 2017 Nov 21;8(64):107666-107677. doi: 10.18632/oncotarget.22587. eCollection 2017 Dec 8. Oncotarget. 2017. PMID: 29296196 Free PMC article.

2

Biologic and clinical significance of squamous epithelial dysplasia of the esophagus.

Saeki H, Kimura Y, Ito S, Miyazaki M, Ohga T. Saeki H, et al. Surgery. 2002 Jan;131(1 Suppl):S22-7. doi: 10.1067/msy.2002.119290. Surgery. 2002. PMID: 11821783 Review.

3

Preoperative hyperthermochemoradiotherapy for esophageal carcinoma.

Nozoe T, Saeki H, Ito S, Ohga T, Kitamura K. Nozoe T, et al. Among authors: saeki h. Surgery. 2002 Jan;131(1 Suppl):S35-8. doi: 10.1067/msy.2002.119286. Surgery. 2002. PMID: 11821785 Review.

4

Clinical significance of PEA3 in human breast cancer.

Kinoshita J, Kitamura K, Tanaka S, Sugimachi K, Ishida M, Saeki H. Kinoshita J, et al. Among authors: saeki h. Surgery. 2002 Jan;131(1 Suppl):S222-5. doi: 10.1067/msy.2002.119792. Surgery. 2002. PMID: 11821815

5

Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer.

Saeki H, Oda S, Kawaguchi H, Ohno S, Kuwano H, Maehara Y, Sugimachi K. Saeki H, et al. Int J Cancer. 2002 Mar 1;98(1):8-13. doi: 10.1002/ijc.10163. Int J Cancer. 2002. PMID: 11857377

6

Early report of correlation between the thermal dosage and the treatment effect of hyperthermia in combination with chemoradiotherapy for esophageal cancer patients.

Kitamura K, Ishida M, Kimura Y, Saeki H, Maehara Y, Sugimachi K. Kitamura K, et al. Among authors: saeki h. Hepatogastroenterology. 2002 Nov-Dec;49(48):1560-2. Hepatogastroenterology. 2002. PMID: 12397735

7

Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.

Saeki H, Ito S, Futatsugi M, Kimura Y, Ohga T, Sugimachi K. Saeki H, et al. Anticancer Res. 2002 Nov-Dec;22(6B):3789-92. Anticancer Res. 2002. PMID: 12552994 Clinical Trial.

8

[Evaluation of multi-modality treatment for the patients with advanced esophageal cancer].

Saeki H, Ohga T, Ito S, Futatsugi M, Kimura Y, Kakeji Y, Maehara Y, Nakamura K, Shioyama Y. Saeki H, et al. Fukuoka Igaku Zasshi. 2002 Dec;93(12):259-65. Fukuoka Igaku Zasshi. 2002. PMID: 12632630 Japanese.

9

Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker.

Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K. Nozoe T, et al. Among authors: saeki h. Cancer Lett. 2003 Mar 20;192(1):89-95. doi: 10.1016/s0304-3835(02)00630-4. Cancer Lett. 2003. PMID: 12637157

10

Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma.

Kimura Y, Watanabe M, Ohga T, Saeki H, Kakeji Y, Baba H, Maehara Y. Kimura Y, et al. Among authors: saeki h. Oncol Rep. 2003 Nov-Dec;10(6):1747-51. doi: 10.3892/or.10.6.1747. Oncol Rep. 2003. PMID: 14534690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,274 results

Search Page

Filters